Integra Plus
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Integra Plus
- Generic name
- FERROUS FUMARATE AND POLYSACCHRIDE IRON VITAMIN MINERAL COMPLEX SUPPLEMENT
- Manufacturer
- U.S. Pharmaceutical Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 9e5b9309-e835-4863-ab6f-e3018e38fc64
- SPL ID
- 0d19a181-dd8a-4c0d-be1d-f4884ee74dbb
- Version
- 7
- Effective date
- 2024-04-03
- Source export date
- 2026-09-28
- Source partition
- 14
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0014-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/db99fd80353afecef4949b48edcaa018be72b966b2360184251eb14df43743f9/drug-label-0014-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:40:33
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Integra Plus | openfda.brand_name | |
| generic name | FERROUS FUMARATE AND POLYSACCHRIDE IRON VITAMIN MINERAL COMPLEX SUPPLEMENT | openfda.generic_name | |
| manufacturer name | U.S. Pharmaceutical Corporation | openfda.manufacturer_name | |
| ndc | package | 52747-712-10 | openfda.package_ndc |
| ndc | package | 52747-712-60 | openfda.package_ndc |
| ndc | package | 52747-712-30 | openfda.package_ndc |
| ndc | package | 52747-712-04 | openfda.package_ndc |
| ndc | product | 52747-712 | openfda.product_ndc |
| ndc11 | package | 52747071260 | derived:openfda.package_ndc |
| ndc11 | package | 52747071204 | derived:openfda.package_ndc |
| ndc11 | package | 52747071230 | derived:openfda.package_ndc |
| ndc11 | package | 52747071210 | derived:openfda.package_ndc |
| spl id | 0d19a181-dd8a-4c0d-be1d-f4884ee74dbb | id | |
| spl set id | 9e5b9309-e835-4863-ab6f-e3018e38fc64 | set_id | |
| unii | R5L488RY0Q | openfda.unii | |
| unii | 2679MF687A | openfda.unii | |
| unii | TLM2976OFR | openfda.unii | |
| unii | H7426RGB3L | openfda.unii | |
| unii | 935E97BOY8 | openfda.unii | |
| unii | PQ6CK8PD0R | openfda.unii | |
| unii | 568ET80C3D | openfda.unii | |
| unii | 6SO6U10H04 | openfda.unii | |
| unii | 8K0I04919X | openfda.unii | |
| unii | 68Y4CF58BV | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. WARNING: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. PRECAUTIONS: General: Folic acid in doses above 0.1 mg - 0.4 mg daily may obscure pernicious anemia, in that hematological remission can occur while neurological manifestations remain progressive. Pediatric Use: Safety and effectiveness of this product have not been established in pediatric patients. Geriatric Use: No clinical studies have been performed in patients age 65 and over to determine whether older persons respond differently from younger persons. Dosage should always begin at the low end of the dosage scale and should consider that elderly persons may have decreased hepatic, renal, or cardiac function and or concomitant diseases.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
Adverse Reactions: Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid. Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation) occur occasionally, but are usually mild and may subside with continuation of therapy. Although the absorption of iron is best when taken between meals, giving Integra PlusTM after meals may control occasional G.I. disturbances. Integra PlusTM is best absorbed when taken at bedtime.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.